OMB APPROVAL
| OMB Number: | 3235-0060 | |
| Expires: | March 31, 2006 | |
| Estimated average burden hours per response | 28.0 |
EFFECTIVE AUGUST 23RD, 2004
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 28, 2004
EPIMMUNE INC.
| Delaware | 0-19591 | 33-0245076 | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 5820 Nancy Ridge Drive San Diego, California | 92121 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:(858) 860-2500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Item 8.01 Other Events. | ||||||||
| Item 9.01 Financial Statements and Exhibits. | ||||||||
| SIGNATURES | ||||||||
| INDEX TO EXHIBITS | ||||||||
| EXHHIBIT 99.1 | ||||||||
Item 8.01 Other Events.
On September 28, 2004, Epimmune Inc. issued a press release announcing plans for a Phase 2 study of its EP-2101 vaccine in patients with late stage non-small cell lung (“NCSL”) cancer, based on evidence of relevant biological responses in early clinical trials in both NCSL and colorectal cancer.
Item 9.01 Financial Statements and Exhibits.
| 99.1 | Press Release of Epimmune Inc. dated September 28, 2004. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| EPIMMUNE INC. | ||||
| Date: September 28, 2004 | By: | /s/ Robert De Vaere | ||
| Robert De Vaere | ||||
| Vice President, Finance and Administration, Chief Financial Officer and Secretary | ||||
| (Principal Accounting Officer and Officer duly authorized to sign this report on behalf of the Registrant) | ||||
